Læknaneminn - 01.10.1995, Blaðsíða 45

BLÓÐÞYNNING
Principles and Clinical Practice 3. útg. Philadelphia: J.B.
Lippincott, 1994:3-18.
17. Coutré S, Leung L. Novel antithrombotic therapeutics
targeted against platelet glycoprotein Ilb/IIIa. Annu Rev
Med 1995;46:257-65.
18. Dale J, Abilgaard U. Thrombosis prophylaxis in medical
departments. Statens legemiddelkontroll og
Lakemedelsverket. Workshop, Treatment of venous
thrombosis and pulmonary embolism 1995.
19. Fareed J, Hoppensteadt D, Walenga JM, Bick RL.
Current trends in the development of anticoagulant and
antithrombotic drugs. Med Clin North Am 1994;78:713-
31.
20. Fihn SD. Aiming t'or safe anticoagulation [editorial]. N
Engl .1 Med. 1995;333:54-55.
21. Furie B, Furie BC. Molecular and cellular biology of
blood coagulation. N Engl J Med 1992;326.800-6.
22. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ,
Silverstein MD. Bleeding and thromboembolism during
anticoagulant therapy: A population-based study in
Rochester, Minnesota. Mayo Clin Proc 1995;70:725-33.
23. Gull0v AL, Koefoed BG, Petersen P.
Blodningskomplikationer til Peroral
Anticoagulansbehandling. Nord Med 1995; 110:114-18.
24. Gurfinkel EP, Manos EJ, Mejaíl RI, Cerdá MA, Duronto
EA, García CN et al. Low molecular weight heparin
versus regular heparin or aspirin in the treatment of
unstable angina and silent ischemia. J Am Coll Cardiol
1995;26:313-8.
25. Harker LA, Maraganore JM, Hirsh J. Novel
antithrombotic agents. í: Colman RW. Hirsh J. Marder
VJ, Salzman JB, ritstj. Hemostasis and Thrombosis:
Basic Principles and Clinical Practice 3. útg.
Philadelphia: J.B. Lippincott, 1994: 1638-61.
26. Hennekens CH, O’Donnell CJ, Ridker PM. Current and
future perspectives on antithrombotic therapy of acute
myocardial infarction. European Heart Journal 1995; 16
(Supplement D):2-9.
27. Hirsh J, Fuster V Guide to anticoagulant therapy part 2:
Oral anticoagulants. Circulation 1994;89:1469-80.
28. Hirsh J, Fuster V Guide to anticoagulant therapy part 1:
Heparin. Circulation 1994;89:1449-68.
29. Hirsh .1, Ginsberg JS, Marder VJ. Anticoagulant Therapy
with Coumarin Agents. í: Colman RW, Hirsh J, Marder
VJ, Salzman JB, ritstj. Hemostasis and Thrombosis:
Basic Principles and Clinical Practice 3. útg.
Philadelphia: J.B. Lippincott, 1994: 1567-83.
30. Hirsh J. Heparin. N Engl J Med 1991 ;324:1565-74.
31. Hirsh J. The optimal duration of anticoagulant therapy
for venous thrombosis [editorial]. N Engl J Med
1995;332:1710-11.
32. Hoffbrand AV, Pettit JE. Platelets, blood coagulation and
haemostasis. í Hoffbrand AV, Pettit JE. Essential
Haematology. 3. útg. Blackwell 1993:299-317.
33. Horn A. Thrombosis prophylaxis in surgical patients.
Statens legemiddelkontroll og Lakemedelsverket.
Workshop, Treatment of venous thrombosis and
pulmonary embolism 1995.
34. Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A.
Comparison of bleeding complications of warfarin plus
acetylsalicylic acid: a study in 3166 outpatients. J Intern
Med 1994:236:299-304.
35. Hylek EM, Singer DE. Risk factors for intracranial
hemorrhage in outpatients taking warfarin. Ann Intern
Med 1994;120:897-902.
36. Johnson PH. Hirudin: Clinical potential of a thrombin
inhibitor. Annu Rev Med. 1994;45:165-77.
37. Kakkar VV Prevention and management of venous
thrombosis. British Medical Bulletin 1994;50:871-903.
38. Kinch JW, Davidoff R. Prevention of embolic events
after cardioversion of atrial fibrillation. Arch Intern Med
1995;155:1353-60.
39. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding:
clinical epidemiology, prediction and prevention, Am J
Med 1993;95:315-28.
40. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein
Ilb/IIIa receptors in cardiovascular medicine. N Engl J
Med 1995;332:1553-59.
41. Lefkovits J. Topol EJ. Direct thrombin inhibitors in
cardiovascular medicine. Circulation 1994;90:1522-36.
42. Leizorovicz A, Simonneau G, Decousus H, Boissel JP.
Comparison of efficacy and safety of low molecular
weight heparin in initial treatment of deep venous
thrombosis: A meta-analysis. BMJ 1994;309:299-304.
43. Ly B. Management of pulmonary embolism. Statens
legemiddelkontroll og Lakemedelsverket. Workshop,
Treatment of venous thrombosis and pulmonary
embolism 1995.
44. McMurray, Rankin R. Cardiology-LTreatment of
myocardial infarction, unstable angina and angina
pectoris. BMJ 1994;309:1343-50.
45. McMurray, Rankin R. Cardiology-ILTreatment of heart
failure and atrial fibrillation and arrythmias.. BMJ
1994;309:1631-5.
46. Moran N, FitzGerald GA. Mechanism of action of
antiplatelet drugs. í: Colman RW, Hirsh J, Marder VJ,
Salzman JB, ritstj. Hemostasis and Thrombosis: Basic
Principles and Clinical Practice 3. útg. Philadelphia: J.B.
Lippincott, 1994: 1623-36.
47. Nielsen FIK, Lassen JF, Ravn HB. Husted SE.
Anticoagulansbehandling og trombolyse ved dyb venos
trombose og lungeemboli. Ugeskr Læger
1995;157:2835-40.
48. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med
1994;330:1287-94.
49. Prandoni P, Lensing AWA, Búller HR, Carta M, Cogo A,
Vigo M. Comparison of subcutaneous low-molecular-
weight heparin witli intravenous standard heparin in
proximal deep vein thrombosis. Lancet 1992;339:441 -
45.
LÆKNANEMINN 2. tbl. 1995 48. árg.
35